Sign in Create account

Alivus Life Sciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ALIVUS BSE: 543322
₹1379.30
▲ 22.50 (1.66%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
71/100
Strong
Valuation
45/100
Fairly Valued
Momentum
51/100
Neutral

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹16,929 Cr
PE (TTM)
28.1
Industry median 36.1 (152 companies)
Price to Book
5.1
PEG (TTM)
1.3
Institutions holding %
12.72%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
31.8
Relative return vs Sector, qtr %
21.4
Free Cash Flow
₹258 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
31.58%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
21.66%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
7.93%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
31.71%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
6.41%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
5.21
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
148.49
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
25.00%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
33.34%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
31.11%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
14.17%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
21.78%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
16.94%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

6 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (16.9%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.7%
Low 1350.0000 · High 1390.0000
1W return
-0.3%
Low 1328.6000 · High 1396.7000
1M return
-1.9%
Low 1317.6000 · High 1470.1000
52W return
47.0%
Low 819.0000 · High 1493.8000
Lifetime High ₹1443.7000 (Sept. 1, 2026)
Lifetime Low ₹374.5500 (Feb. 22, 2023)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
1368.4
10D
1372.7
20D
1372.9
50D
1325.2
100D
1236.8
200D
1079.9

Delivery and volume

Day avg. delivery
52.9%
Week avg. delivery
53.6%
Month avg. delivery
55.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1373.10
Pivot
First resistance1396.20
Second resistance1413.10
Third resistance1436.20
First support1356.20
Second support1333.10
Third support1316.20
Day RSI52.6
Day MFI37.2
Day MACD6.92
Day MACD signal14.37

Beta

1M0.85
3M0.64
1Y0.60
3Y0.50

Price change analysis

↓ -1.9%
Over 1 Month
LowHigh
1317.601470.10
↑ 21.4%
Over 3 Months
LowHigh
1086.101493.80
↑ 40.1%
Over 6 Months
LowHigh
957.001493.80
↑ 47.0%
Over 1 Year
LowHigh
819.001493.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 28.1 (own history: 20.2–30.6)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹640 Cr
Net profit (June 30, 2026)
₹160 Cr
Basic EPS (June 30, 2026)
₹13.0400

Ranks #33 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter74.87%
  • Mutual funds5.65%
  • FII/FPI5.54%
  • Other DII1.53%
  • Public12.41%

Largest holders

NameCategoryShares %Shares
Nirma LimitedPromoter74.8700%91896285
Quant Mutual Fund - Quant Small Cap FundPublic2.5100%3080136
Government Pension Fund GlobalPublic2.4000%2950000
Massachusetts Institute of TechnologyPublic1.2300%1504000

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 74.87% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 5.29% to 5.54% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 5.63% to 5.65% in Jun 2026 qtr

8 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 8 insider trades, 0 SAST, 2 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
15 Jul 2024 GLENN SALDANHA Promoter group Sell 0 ₹0
15 Jul 2024 Glenmark Pharmaceutical Limited Promoter Sell 0 ₹0
13 Mar 2024 Glenmark Pharmaceutical Limited Promoter Sell 0 ₹0
13 Mar 2024 Nirma Limited Promoter Buy 0 ₹0
7 Mar 2024 Glenmark Pharmaceuticals Limited Promoter Sell 0 ₹0
25 Sep 2023 Glenmark Pharmaceuticals Limited Promoter Pledge 0 ₹590.99 Cr
17 Nov 2021 GLENN SALDANHA Promoter group Buy 0 ₹0
17 Nov 2021 GLENN SALDANHA Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 3 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
4 Dec 2025 ICICI PRUDENTIAL MUTUAL FUND Bulk Buy 969,912 870.0000 BSE
25 Jan 2024 SOCIETE GENERALE Block Buy 151,173 799.5500 BSE
25 Jan 2024 BNP PARIBAS ARBITRAGE Block Sell 151,173 799.5500 BSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹5.00 per share
Dividend yield 0.36%
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 5.0000 — —
1 Sep 2026 Dividend - Rs 5 Per Share 5.0000 1 Sep 2026
1 Sep 2025 Dividend - Rs 5 Per Share 5.0000 1 Sep 2025
17 Oct 2023 Interim Dividend - Rs 22.50 Per Share 22.5000 17 Oct 2023
24 Mar 2023 Interim Dividend - Rs 21 Per Share 21.0000 24 Mar 2023
15 Sep 2022 Dividend - Rs 10.5 Per Share 10.5000 —
22 Nov 2021 Interim Dividend - Rs 10.50 Per Share 10.5000 23 Nov 2021

Corporate Actions

Full history (9 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Glenmark Life Sciences Limited to ALIVUS LIFE SCIENCES LIMITED
22 Sep 2023OTHERAnnual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
30 Jul 2026 Financial Results Yes
14 May 2026 Financial Results/Dividend Yes
22 Jan 2026 Financial Results Yes
6 Nov 2025 Financial Results Yes
1 Aug 2025 Financial Results Yes

Corporate Announcements

All 348 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
16 Sep 2026 Company Update Alivus Life Sciences Ltd - 543322 - The Company Has Incorporated A Wholly Owned Subsidiary Company In Brazil.
16 Sep 2026 General Updates Alivus Life Sciences Limited has informed the Exchange that the Company has incorporated a wholly owned subsidiary company in Brazil.
11 Sep 2026 Company Update Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
8 Sep 2026 Shareholders meeting Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.
7 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
5 Sep 2026 Company Update Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
25 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Alivus Life Sciences Limited has informed the Exchange about Schedule of Investor/Analyst meeting
18 Aug 2026 Press Release Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQGenX.".

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (25.0%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (148.5x)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Alivus Life Sciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.